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Abstract
Background: Inhibitor of DNA binding 1 (Id1) is a nuclear protein containing a basic helix-loop-helix (bHLH) domain
that regulates cell growth by selective binding and prevention of gene transcription. Sources of Id1 production in
rheumatoid arthritis synovial tissue (RA ST) and its range of functional effects in RA remain to be clarified.
Methods: We analyzed Id1 produced from synovial fibroblasts and endothelial cells (ECs) with histology and real-time
polymerase chain reaction (RT-PCR). Fibroblast supernatants subjected to differential centrifugation to isolate and purify
exosomes were measured for Id1 by enzyme-linked immunosorbent assay (ELISA). Western blotting of Id1-stimulated
ECs was performed to determine the kinetics of intracellular protein phosphorylation. EC intracellular signaling
pathways induced by Id1 were subsequently targeted with silencing RNA (siRNA) for angiogenesis inhibition.
Results: By PCR and histologic analysis, we found that the primary source of Id1 in STs is from activated fibroblasts that
correlate with inflammatory scores in human RA ST and in joints from K/BxN serum-induced mice. Normal (NL) and RA
synovial fibroblasts increase Id1 production with stimulation by transforming growth factor beta (TGF-β). Most of the
Id1 released by RA synovial fibroblasts is contained within exosomes. Endothelial progenitor cells (EPCs) and human
dermal microvascular ECs (HMVECs) activate the Jnk signaling pathway in response to Id1, and Jnk siRNA reverses
Id1-induced HMVEC vessel formation in Matrigel plugs in vivo.
Conclusions: Id1 is a pleotropic molecule affecting angiogenesis, vasculogenesis, and fibrosis. Our data shows that
Id1 is not only an important nuclear protein, but also can be released from fibroblasts via exosomes. The ability of
extracellular Id1 to activate signaling pathways expands the role of Id1 in the orchestration of tissue inflammation.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by inflammation and joint destruction.
Angiogenesis is important in a variety of vasculoprolifera-
tive states such as wound repair and RA synovitis. Many
inflammatory mediators found in RA synovial tissues
(STs) and synovial fluids (SFs) display angiogenic proper-
ties. Inhibitor of DNA binding 1 (Id1) is a member of the
helix-loop-helix (HLH) family of transcription factors and
a marker of cellular self-renewal. Inhibition of Id1 in the
bone marrow (BM) results in significant decreases in
endothelial progenitor cell (EPC)-linked tumor-associated
vasculogenesis [1]. Gao et al. showed that it was possible
to identify, track, and target BM-derived endothelial EPCs
in vivo using a mouse model of pulmonary metastasis by
measurement of Id1 expression [1, 2].
Id1 lacks DNA binding activity, but instead forms
heterodimers with members of the basic helix-loop-helix
(bHLH) family of transcription factors, allowing Id1 to
inhibit DNA binding and transcriptional activation of
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proteins with which it interacts. bHLH proteins such as
BMAL1-Clock (circadian locomotor output cycles
kaput) [3], which is a core transcription complex in the
molecular circadian clock, bind Id1. Id1 also interacts
with various genes, such as c-Myc [4] and hypoxia-
inducible factor-1 (HIF-1) [5], that have been linked to
cancer due to their effects on cell growth and metabol-
ism. Id1 binds tightly to ubiquitously expressed E pro-
teins, that heterodimerize with tissue-restricted bHLH
proteins to form active transcription complexes. By
sequestering E proteins, Id1 inhibits tissue-restricted
gene expression in multiple cell lineages using the same
biochemical mechanism [6, 7].
The human Id1 gene has been cloned and character-
ized by Hara et al. [8], who also cloned a related gene,
Id2. A splice variant (Id1-prime) that does not show the
growth-regulated expression normally seen with Id1 has
also been described [9]. The Id1-related proteins Id2 and
Id3 [10] are also negative regulators of pluripotent stem
cell maturation [11]. As a protein affecting the activity of
many transcription factors, Id1 can affect multiple cellu-
lar properties. Targeting of Id1 transcription blocks EPC
mobilization, causes angiogenesis inhibition, impairs the
spread of metastasis, and increases the survival of
tumor-bearing mice [1, 2]. Interestingly, human Id1
mRNA is barely detectable in quiescent early-passage
fibroblasts, but its expression can be induced by serum.
Moreover, Id1 antisense RNA prevents early-passage
fibroblasts from entering the S phase of the cell cycle [8].
Histologic analysis of ST revealed that Id1 is highly
expressed in the vasculature of RA ST [12], and also in
synoviocytes (SNCs). Sakurai et al. also showed substantial
expression of Id1 and Id3 in RA compared to osteoarth-
ritis (OA) synovium at the protein and transcriptional
levels [13]. Our group was the first to report that RA syn-
ovial fluid (SF) contains abundant amounts of Id1, and we
now show that the primary source is not from EPCs or
endothelial cells (ECs), but from RA ST fibroblasts. We
also show that Id1 is packaged within extracellular vesicles
(EVs) and released from fibroblasts via exosomes. Lastly,
we provide evidence that Id1 activates EC signaling path-
ways, inducing angiogenic responses [12], which can be
targeted to reduce blood vessel growth.
Methods
Ethical use of animals
Procedures involving animals in this study were approved
by The University Committee for the Use and Care of
Animals (UCUCA) at the University of Michigan. Mice
were housed in sterile rodent micro-isolator caging with
filtered cage tops in a specific pathogen-free environment.
Severe combined immunodeficient (SCID) mice were ob-
tained from the National Cancer Institute (NCI). C57/BL6
wildtype (Wt) mice were bred in house. All efforts were
made to reduce stress or discomfort in the animals used
in these studies.
Patient samples
STs were obtained from RA patients undergoing total
joint replacement who met the American College of
Rheumatology criteria for RA. Prior to surgery unrelated
to the proposed research, patients were asked whether
they were willing to contribute ST to the study. ST
specimens were stored at -80 °C. All human specimens
were consented for use in this study by the Institutional
Review Boards of the University of Michigan Medical
School (IRBMED).
K/BxN serum-induced arthritis model
To generate arthritic K/BxN mice, K/B-positive mice
were crossed with NOD/LTj mice as previously de-
scribed [14]. Naïve C57BL/6 mice at the age of 5–7
weeks were injected with 150 μL of K/BxN serum intra-
peritoneally, and this was considered day 0 of arthritis.
Another injection of 150 μL of K/BxN serum followed
on day 2. Robust arthritis with severe swelling of the
joints typically developed on day 5. Articular index (AI)
scores and joint circumferences were determined start-
ing on day 0 and scored at least every other day up to
day 23 after induction of arthritis, as described previously
for rat adjuvant-induced arthritis [15]. Clinical scoring for
arthritis was performed using a 0–4 AI scale, where 0 = no
swelling or erythema, 1 = slight swelling and/or erythema,
2 = low-to-moderate edema, 3 = pronounced edema with
limited use of the joint, and 4 = excessive edema with joint
rigidity. All measurements were taken by observers
blinded to the experimental conditions. Mouse ankles
were harvested for histology.
Immunohistochemisty (IHC)
RA, OA, and normal (NL) (no arthritis) ST cryosections
as well as ankle sections of Wt mice induced with K/BxN
serum were fixed in cold acetone for 30 min at 4 °C. The
tissue sections were blocked with 5 % donkey serum and
20 % fetal bovine serum (FBS) in phosphate-buffered
saline (PBS) at 37 °C for 1 h. The sections were then
incubated with either mouse anti-human Id1 antibody
(Abcam, Cambridge, MA, USA, 10 μg/mL), rabbit anti-
mouse Id1 antibody (CalBioreagents, San Mateo, CA,
USA, 10 μg/mL), or purified nonspecific mouse and rabbit
immunoglobulin G (IgG) (Thermo Fisher Scientific,
Waltham, MA, USA) for 1 h at 37 °C in blocking buffer.
After washing, tissues were incubated with a biotinylated
anti-mouse or anti-rabbit secondary antibody (Vector
Laboratories, Burlingame, CA, USA, 10 μg/mL) for 1 h at
37 °C in blocking buffer. Vectastain ABC kit (Vector
Laboratories) was used to detect the antibodies on the tis-
sues, following manufacturer’s protocols. Sections were
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mounted with Cytoseal 60 (Thermo Fisher Scientific),
visualized under an Olympus microscope (Olympus,
Tokyo, Japan) and scored by a pathologist.
Immunofluorescence histology
RA, OA, and NL ST sections were fixed in cold acetone
for 30 min. The STs were blocked with 5 % donkey
serum and 20 % FBS in PBS at 37 °C for 1 h, and then
incubated with rabbit anti-human Id1 antibody (Abcam,
10 μg/ml) or purified nonspecific rabbit IgG for 1 h at
37 °C in blocking buffer. The synovial tissue samples
were washed with PBS, and a 1:200 dilution in blocking
buffer of fluorescent-conjugated donkey anti-rabbit anti-
body was added, and incubated for an additional 1 h at
37 °C. Finally, slides were washed, dried, coverslipped
and viewed under a fluorescence microscope (×400).
Cell culture
EPCs (CD34+ cells from cord blood) were isolated from
cord blood from granulocyte-colony stimulating factor
(G-CSF)-mobilized leukopheresis samples on the basis
of CD133 expression, using an antibody-coupled mag-
netic bead cell isolation system (Stemcell Technologies,
Vancouver, BC, Canada) as previously described [16].
Human umbilical cord blood was collected by the
method of Moore et al. [17], as previously described
[16]. To confirm purity of the EPCs, isolated cell popula-
tions were subjected to flow cytometry analysis as de-
scribed previously [18, 19]. EPCs with appropriate cell
markers (CD34+, CD133+, CD14-) were used in cell sig-
naling studies.
Human dermal microvascular ECs (HMVECs) as well
as all fibroblasts were collected from human tissues,
which were digested in a cell culture media supple-
mented with FBS, collagenase, and hyaluronidase as
done previously [20–22]. HMVECs were isolated from
skin biopsies while the fibroblasts were isolated from
synovial tissues of arthritis patients obtained at arthroplasty
or synovectomy. HMVECs were isolated and purified using
CD31 microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany). HMVECs were grown in EBM-2 (Lonza,
Walkersville, MD, USA) and were placed in reduced-
serum EBM-1 before stimulation. EBM-1 without serum
was used for HMVEC stimulations. EPCs were grown and
stimulated in StemSpan SFEM (Stemcell Technologies)
with no added supplement. Fibroblasts were grown in
RPMI-1640 (Thermo Fisher Scientific) supplemented with
10 % FBS and were stimulated in serum free RPMI-1640.
Id1 enzyme-linked immunosorbent assay (ELISA)
HMVECs, EPCs, monocytes, and RA, OA, and NL syn-
ovial fibroblasts were plated in 6-well plates at 200,000
cells/well and serum starved overnight. Media was ex-
changed and collected after 24 h. The collected media
was analyzed by ELISA for Id1 (MyBioSource, San
Diego, CA, USA). Manufacturer protocols were fol-
lowed. SFs of RA, OA, and several other diseases were
also analyzed by this ELISA. Both synovial and dermal
fibroblasts were stimulated with varying cytokines and
concentrations. Cytokines used were tumor necrosis
factor alpha (TNF-α, Thermo Fisher Scientific), chemo-
kine (C-X-C motif) ligand 16 (CXCL16, R&D Systems,
Minneapolis, MN, USA), interleukin 17 (IL-17, R&D
Systems), and TGF-β (R&D Systems). These cytokines
were chosen because they are known to be upregulated in
RA ST [23, 24]. The supernatant and exosome fractions
were collected after 24 h and analyzed by this ELISA.
RNA extraction and quantitative real-time polymerase
chain reaction (RT-PCR)
Total RNA was isolated from synovial fibroblasts and
HMVECs using RNAeasy mini RNA isolation kits in
conjunction with QIAshredders (Qiagen, Valencia, CA,
USA) following the manufacturer’s protocol. Following
isolation, RNA was quantified and checked for purity
using a Nanodrop spectrophotometer (Thermo Fisher
Scientific). cDNA was then prepared using a Verso cDNA
kit (Thermo Fisher Scientific) as per the manufacturer’s
protocol. Quantitative PCR (qPCR) was performed using
Platinum SYBR Green qPCR SuperMix-UDG (Thermo
Fisher Scientific) following the manufacturer’s protocol.
The primer pairs used were based on published se-
quences. Diluted cDNA was mixed with Platinum SYBR
green qPCR SuperMix-UDG, forward and reverse primers
specific for each gene (10 μM final concentrations), and
incubated at the following cycles; 50 °C for 2 min, 95 °C
for 2 min and 40 cycles of 95 °C for 30 s, 55 °C for 30 s
and 68 °C for 30 s using an ABI Prism 7500 sequence
detection system (Applied Biosystems, Foster City, CA,
USA). The primers for human Id1 [25], are forward:
AGAACCGCAAGGTGAGCAA and reverse: CCAACT
GAAGGTCCCTGATGTAG. The primers used for β-
actin were used previously, [12, 26] and are forward:
GCTAGGCAGCTCGTAGCTCT and reverse: GCCATG
TACGTTGCTATCCA. All samples were run in duplicate.
Exosome purification
Exosomes were isolated from cell culture supernatants
by differential centrifugation. RA synovial fibroblasts
were plated at 200,000 cells/well in a 6-well tissue cul-
ture plate in serum-free media. Media was exchanged
and incubated for 24 h after which the supernatant was
collected. An aliquot of the supernatant was taken for
later analysis and the remaining amount was subjected
to several steps of differential centrifugation. All centri-
fugation was conducted at 4 °C. First, the supernatant
was centrifuged at 300 × g for 10 min to remove free
cells. The remaining supernatant was centrifuged at
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10,000 × g to remove cellular debris, then at 30,000 × g
to remove smaller debris. The supernatant was then
transferred to an ultracentrifuge and spun at 110,000 × g
overnight to pellet the exosomes. The supernatant was
stored and the pellet was separated on an Optiprep
density gradient (Sigma-Aldrich, St. Louis, MO, USA).
The fractions containing exosomes were then isolated.
Notably, exosomes isolated from RA and OA SFs were
isolated similarly from rheumatoid factor-depleted SFs.
The original whole supernatant, exosome and cellular
debris-depleted fractions, exosome fractions, exosomes
isolated from SFs as well as exosome fractions lysed with
0.5 % Triton X-100 (Sigma-Aldrich) were individually
analyzed using the Id1 ELISA.
Western blotting
HMVECs or EPCs were plated in 6-well plates at 500,000
cells/well and serum starved overnight. The wells were
then stimulated with Id1 (Abnova, Taipei, Taiwan, 10 nM)
over a 45-min time course. Cell lysates were prepared in
reducing conditions and western blot analysis was done.
Proteins were transferred from the gel to nitrocellulose
membranes which were then blocked in 5 % nonfat dry
milk in Tris-buffered saline + Tween 20 (TBST, pH 7.6).
Membranes were probed with rabbit anti-human anti-
bodies to both the phosphorylated (*p) and nonpho-
sphorylated forms of Jnk, Erk1/2, PI3k, and P38 (Cell
Signaling Technology, Danvers, MA, USA, 1:1000 dilu-
tion) in blocking buffer overnight at 4 °C. Membranes
were washed three times with TBST and incubated with
horseradish peroxidase (HRP)-conjugated donkey anti-
rabbit antibody (Cell Signaling Technology, 1:1000
dilution) for 1 h at 25 °C. Membranes were washed with
TBST and visualized using Pierce ECL Western Blotting
Substrate (Thermo Fisher Scientific). X-ray film was used
to visualize the blots after ECL. These films were scanned
and bands were quantified by UN-SCAN-IT (Silk
Scientific, Orem, UT, USA). Gel loading was accounted
for by adjusting all phosphorylated data by the total
amount of signaling protein, and fold change of the phos-
phorylated signal molecules was calculated with respect to
the unstimulated lysate.
Severe combined immunodeficiency (SCID) Matrigel plug
angiogenesis assay
To examine the effects of the Jnk pathway in angiogenesis
with Id1 stimulation in vivo, SCID mice were injected sub-
cutaneously with sterile Matrigel (Corning Life Sciences,
Tewksbury, MA, USA, 500 μL/injection) containing Id1
(10 nM) and Jnk-silenced HMVECs. HMVECs were
silenced using silencing RNA (siRNA) inhibiting the Jnk
signaling molecule (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Either Jnk siRNA or nonspecific siRNA
was transfected into the HMVECs using the TransIT-
TKO Transfection Reagent (Mirus Bio, Madison, WI,
USA). Manufacturer’s protocols were followed for the
transfection. Twenty-four hours after transfection, some
of the cells were lysed to confirm Jnk knockdown and the
rest were injected into mice together with the Matrigel
(2.5 × 105 cells/injection). The Matrigel plugs were removed
5 days later and weighed. Hemoglobin (Hb) analysis was
conducted on the plug homogenates as a measure of
angiogenesis. Hb levels were measured by adding 25 μL of
homogenate mixed with 25 μL of 3, 3′, 5, 5′-tetramethyl-
benzidine (TMB) reagent to 96-well plates. Finally, samples
were incubated at room temperature for 5 min. Absorbance
was read with a microplate reader at 450 nm. Hb concen-
tration was determined by comparison with a standard
curve in mg/mL. Hb concentration, after normalization
with plug weight, is a reflection of the number of blood ves-
sels in the tissue [27].
Statistics
Statistical analysis
Results are expressed as the mean ± standard error of
the mean (SEM). Data were analyzed using a Student’s t
test. P values less than 0.05 were considered significant.
For histology data on cryosections from human and
rodent synovial tissues, all cells were considered for
positive or negative Id1 staining by a board-certified
pathologist blinded to the experimental setup. The re-
sults are presented as the percentage of positive cells in
each section. At least three sections were evaluated (for
both mouse and human specimens) and the results were
averaged, then pooled in the respective groups for all
tissues evaluated.
Results
RA ST fibroblasts express Id1
Total RNA was isolated from nonstimulated ST fibro-
blasts and HMVECs. There was a significantly elevated
Id1 mRNA expression in RA compared to NL ST fibro-
blasts and HMVECs, showing that Id1 production is
upregulated in activated fibroblasts compared to NL ST
fibroblasts or ECs (Fig. 1a).
Immunohistochemical analysis of Id1 expression in mouse
and human synovium
IHC staining for Id1 on RA, OA, and NL STs and K/BxN
serum-induced mouse ankles indicated the presence of
Id1 in these tissues. Id1 was highly expressed on SNCs of
RA ST as well as in the K/BxN serum-induced mouse an-
kles (Figs. 1b, c and 2a–c). Immunofluorescence histology
further validated the Id1 staining pattern seen with IHC
(Fig. 1c). Analysis of these tissues by a pathologist revealed
that RA STs had a significantly higher percentage of SNCs
positive for Id1 than did OA and NL STs (Fig. 2a). Simi-
larly, the day 12 K/BxN serum-induced mouse ankles had
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more Id1-positive SNCs than day 0 mouse ankles;
although the difference was less striking (Fig. 2b and c).
All images were taken at ×400.
Effects of cytokines on fibroblast expression of Id1
Analysis of supernatants of unstimulated cells of several
types found in the RA synovium showed that synovial
fibroblasts are the primary producer of Id1, and that RA
fibroblasts produce more basal Id1 compared to NL and
OA fibroblasts (Fig. 3a). Monocytes also produce some
Id1, however much less compared to synovial fibroblasts.
The ECs produced an undetectable amount of Id1.
ELISA analysis of cell culture supernatants of NL syn-
ovial fibroblasts stimulated with various cytokines
showed that TGF-β (at 10 and 50 ng/mL) and to a lesser
extent IL-17 (at 50 ng/mL) increased Id1 production
(Fig. 3b). TNF-α and CXCL16 had only minor effects on
the secretion of Id1 by these cells. ELISA analysis of RA,
OA, and NL synovial fibroblast cell culture supernatants
stimulated with TGF-β at 10 and 50 ng/mL showed that
TGF-β had a large effect on Id1 production by synovial
fibroblasts (Fig. 3c). RA fibroblasts were significantly
more sensitive to TGF-β stimulation with respect to
Id1 production compared to OA and NL synovial
fibroblasts.
Identification of Id1 in fibroblast exosomes
Analysis of fractions taken during a successive series of
steps to isolate exosomes using differential centrifuga-
tion from RA synovial cell supernatants showed that the
majority of the Id1 is found within exosomes when com-
pared to the other fractions (Fig. 4). A small amount of
Id1 was found in the whole supernatant and exosome-
depleted fractions, and no Id1 was found in the unlysed
exosome fraction. Triton X-100 at 0.5 % was used to lyse
the exosomes and the majority of Id1 was found in this
fraction. Notably, exosomes isolated from RA and OA
SFs showed very low levels of Id1 unless the exosomes
were disrupted by treatment with Triton X-100, confirm-
ing that Id1 is largely packaged within cellular exosomes
and distributed outside of the cell (Fig. 2e).
Western blot analysis of Id1-mediated signaling in ECs
Western blot analysis of *pJnk in HMVECs and EPCs
following stimulation with Id1 showed that *pJnk was
upregulated after 1 min of stimulation with Id1, an effect
that persisted for at least 45 min in EPCs. However, in
HMVECs upregulation was delayed by 15 min and was
less robust, but continued to 45 min (Fig. 5a and b).
Analysis of *pP38 in EPCs showed that *pP38 was up-
regulated almost immediately after stimulation with Id1
and this effect persisted at 45 min of stimulation (Fig. 5c).
*pErk and *pPI3k did not show any upregulation after
Id1 stimulation in either EPCs or HMVECs and *pP38
did not show any upregulation in HMVECs after Id1
stimulation (Fig. 5e). Results are shown as fold increase
from nonstimulated (NS) cells arbitrarily set at 1. Upper
bands represent phosphorylated signaling molecules (p)
Fig. 1 Id1 is expressed in ECs and ST fibroblasts. a mRNA was isolated
from HMVECs and fibroblasts were isolated from NL and RA ST. mRNA
was reverse transcribed into cDNA and underwent PCR for 40 cycles.
RA fibroblasts showed significantly elevated Id1 expression compared
to NL ST fibroblasts and HMVECs. b Id1 is expressed in RA STs. IHC was
performed on RA, OA, and NL ST cryosections. Tissues were blocked
and then incubated using a mouse anti-human Id1 (Abcam) primary
antibody. After washing, tissues were incubated with a biotinylated
anti-mouse secondary antibody (Vector Laboratories). Tissues were
washed and subsequently developed with the Vectastain ABC kit
(Vector Laboratories). Id1 is found on synovial cells (SNC) in the RA ST.
c For immunofluorescence staining, RA, osteoarthritis (OA), and normal
(NL) ST sections were fixed in cold acetone for 30 min. The STs were
blocked with 5 % donkey serum and 20 % fetal bovine serum (FBS) in
PBS at 37 °C for 1 h, and then incubated with rabbit anti-human Id1
antibody (Abcam, 10 μg/ml) or purified nonspecific rabbit IgG for
1 h at 37 °C in blocking buffer. The synovial tissues samples
were washed with PBS, and a 1:200 dilution in blocking buffer
of fluorescent-conjugated donkey anti-rabbit antibody was added and
incubated for an additional 1 h at 37 °C. As shown, we could validate
Id1 staining in RA ST similar to what was found using IHC (×400).
FLS fibroblast-like synoviocytes, HMVEC human dermal microvascular
endothelial cell, Id1 inhibitor of DNA binding 1, IgG immunoglobulin,
NL normal, RA rheumatoid arthritis, SNC synovial cell
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and the bottom bands represent the total signaling mol-
ecule for each respective protein. Independent lysates
were run for both phosphorylated and total amounts of
signaling proteins, and a representative blot is shown
above each graph in Fig. 5. Using these bands from each
respective blot, the amount of phosphorylated signaling
molecule was quantified and the results were pooled.
Id1 induces angiogenesis in vivo
Hemoglobin analysis of Matrigel plugs injected into
SCID mice with HMVECs and 10 nM Id1 showed less
hemoglobin when the HMVECs were pretreated with
Jnk siRNA compared to the control siRNA (Fig. 6).
Hemoglobin concentration is representative of vascu-
larization of the Matrigel plug. The results indicate that
Id1 signaling through Jnk mediates the angiogenic effect
of extracellular Id1.
Discussion
Id1 is known to be a nuclear transcription factor charac-
teristic of EPCs and cells that display a hyperproliferative
phenotype. Our group has previously shown that Id1 is
detected in RA synovium and SFs, and displays pro-
angiogenic activity as an extracellular agonist [12]. Levels
of Id1 are elevated in RA SFs and correlate with expres-
sion of the angiogenic chemokine CXCL16 (the ligand
for the CXCR6 receptor) [12]. Correspondingly, CXCR6
knockout mice develop attenuated angiogenesis associ-
ated with profound decreases in arthritis progression
and inflammatory cell recruitment to arthritic joints in
K/BxN serum-induced mice. We now present evidence
that synovial fibroblasts are largely responsible for the
elevated amounts of Id1 in RA SF, and that appro-
ximately 80 % of the Id1 released by fibroblasts is
packaged within exosomes. Moreover, pro-inflammatory
cytokines known to be elevated in RA patients, such as
IL-17 and especially TGF-β, induce significantly more
fibroblast-derived Id1 in RA compared to OA or NL
fibroblasts in vitro. Of special note, RA fibroblasts are
significantly more sensitive to TGF-β stimulation than
OA or NL fibroblasts with respect to Id1 production.
These findings indicate that RA fibroblasts are primed
to release Id1 in response to pro-fibrotic and angiogenic
mediators, potentially due to epigenetic alteration of
these cells in vivo.
Histologic analysis of ST revealed that Id1 is highly
expressed on synovial SNCs and in the vasculature of the
RA ST [12] in complete agreement with Sakurai et al.,
who showed Id1 and Id3 mRNA and protein are elevated
in RA synovium [13]. Studies of knockout mice lacking
expression of Id1 have shown its involvement in vasculo-
genesis and neuroblast differentiation in various cancer
K/BxN Mouse Ankle
a
c
b
Fig. 2 SNC Id1 expression is significantly higher in inflamed ST and in the ankles of K/BxN serum-induced mice. a Id1 expression was visualized
on SNCs in ST by IHC. A significantly greater percentage of SNCs were positive for Id1 in RA compared to OA and NL ST. b Percentages of cells
expressing Id1 were also evaluated on SNCs from joint tissues taken from K/BxN serum-induced mice. A significantly greater percentage of SNCs
positive for Id1 compared to Wt (noninduced mice) was found. c Murine tissues were blocked and then incubated using a rabbit anti-mouse Id1
antibody (CalBioreagents). After washing, tissues were incubated with a biotinylated anti-rabbit secondary antibody (Vector Laboratories). Tissues
were washed and subsequently developed with the Vectastain ABC kit (Vector Laboratories). Id1 is found on SNCs near the bone in the K/BxN
mouse ankles. Id1 inhibitor of DNA binding 1, IgG immunoglobulin, NL normal, OA osteoarthritis, RA rheumatoid arthritis, SNC synovial cell,
ST synovial tissue, Wt wildtype
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models normally characterized by extensive vascular-
ization [28]. Tumors transplanted into these mice failed to
grow and metastasize due to lack of proper tumor angio-
genesis. Branching and sprouting of blood vessels in the
neuroectoderm is also defective in double knockout mice
lacking expression of Id1 and the related Id3, as these ani-
mals show premature differentiation of neuroblasts [28].
Thus it appears that Id1 expression is critical for angio-
genic processes found in the tumor microenvironment or
the RA joint, further suggesting that dysregulation of Id1
can lead to unwanted inflammatory outcomes. Further-
more, our findings provide additional evidence that Id1
may be used to assess or grade the severity of pathologic
inflammatory conditions, as has been done previously for
some cancers [29].
One of the many interesting features of Id1 is its
ability to repress inhibitors of angiogenesis. Previous
studies showed that Id1 indirectly regulates angiogenesis
through transcriptional repression of thrombospondin-1
(TSP-1) [30]. Interestingly, a recent study showed that
TSP-1 is strongly expressed by RA ST fibroblasts in-
duced by TGF-β [31], both at the transcriptional and
translational levels. This finding could raise questions
about the role for Id1 repression of TSP-1. One possible
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Fig. 3 RA ST fibroblasts secrete Id1 and upregulate Id1 expression upon stimulation with TGFβ. a EPCs, HMVECs, monocytes, NL, RA, and OA
fibroblasts were plated and serum starved. Cell culture media was replaced and the supernatants were collected 24 h later. The cell culture
supernatants were examined for Id1 expression by ELISA (MyBioSource). EPCs, HMVECs as well as all fibroblasts were collected from human
tissues, which were digested in a mix of cell culture media supplemented with FBS, collagenase, and hyaluronidase. HMVECs were isolated from
skin biopsies while the fibroblasts were isolated from STs of patients with either RA, OA, or from NL patients. HMVECs were isolated and purified
using CD31 microbeads (Miltenyi Biotec). All cell lines were between passages 3 and 6. No cytokine stimulation was used. b NL fibroblasts were
plated and serum starved under the same conditions as panel a. Cell culture media with the respective cytokine was exchanged and collected
24 h later. CXCL16 (R&D Systems), IL-17 (R&D Systems), TNF-α (Life Technologies) and TGF-β (R&D Systems) were used at 10 ng/mL and 50 ng/mL
concentrations. A not stimulated (NS) well was also used with no added cytokine (n = number of experimental replicates). c Synovial fibroblasts
were plated under the same conditions as panel a. Cell culture media with TGF-β was exchanged and collected 24 h later. CXCL16 chemokine
(C-X-C motif) ligand 16, EPC endothelial progenitor cell, HMVEC human dermal microvascular endothelial cell, Id1 inhibitor of DNA binding 1, IL-17
interleukin 17, NL normal, NS nonstimulated, OA osteoarthritis, RA rheumatoid arthritis, TGF-β transforming growth factor beta, TNF-α tumor necrosis
factor alpha
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explanation for this discrepancy may be that TGF-β
could directly induce TSP-1 expression in RA, poten-
tially overriding any transcriptional control exerted by
Id1. Moreover, TSP-1 has also been shown to upregulate
TGF-β in experimental inflammatory glomerular disease.
Thus it appears that TGF-β and TSP-1 may upregulate
expression of the other, making it tempting to speculate
that upregulated Id1 serves as a negative control mech-
anism for TSP-1 and TGF-β expression [32].
The expression of diverse genes involved in remodeling
of the extracellular matrix, angiogenesis, and intracellular
signaling are also affected by Id1 [30]. Furthermore, Id1
represses p21 expression [4] to control EPC growth and
maturation in the BM. Because of the ability of Id1 to
downregulate expression of these potent repressors, it was
reported that Id1 can function as an effective pro-
angiogenic mediator produced by EPCs and pluripotent
stem cells [33]. This idea was reinforced by reports identi-
fying Id1 and Id3 as negative regulators of pluripotent
stem cell maturation [11]. Because of its potent regulatory
control of angiogenic and vasculogenic processes, it was
not surprising to find that Id1 acts as a negative transcrip-
tional regulator for proteins associated with malignant
melanoma development [34, 35].
It is well documented that Id1 is a regulatory nuclear
protein, however, we and others have previously shown
that Id1 can be detected on the ECs in the RA synovium
and in soluble form in synovial effusions [12, 13]. This
suggests that Id1 travels outside the nucleus, but the
functionality and method of this transfer has not been
previously described. One possibility is that Id1 may be
packaged into EVs such as cellular exosomes that can be
released into the joint space or directly into adjacent
cells. To test this possibility, we isolated EVs from RA
synovial fibroblast supernatants known to contain Id1,
and measured Id1 in the EVs and soluble protein frac-
tions. We used differential ultracentrifugation to isolate
EVs specifically around the size of exosomes. We visually
confirmed a band at the density gradient between
fractions 4 and 5, where exosomes would be expected
(density between 1.084 g/mL and 1.163 g/mL). To more
clearly define where Id1 is located, we further subdivided
Fig. 4 Id1 is contained in fibroblast exosomes. Fibroblasts from RA, osteoarthritis (OA), and normal (NL) STs were plated and maintained in CMRL
medium supplemented with 20 % FBS, 2 mM L-glutamine, and 1 % penicillin/streptomycin in T175cm2 flasks and were used between passages 4
and 10. Cultures were moved to serum-free media DMEM/F-12 with Peprogrow serum replacement (Peprotech) for 2 days before harvesting.
Fibroblast culture supernatants were concentrated to 1 mL (per flask) by centrifugation through an Amicon Ultracel 30 K filter (EMD Millipore, Billerica,
MA, USA). Exosomes from cell supernatants were isolated and purified by serial ultracentrifugation. Nanoparticle Tracking Analysis was used to quantify
the size and concentration of particles within the exosome fractions. a and b Cells were spun out at 1500 rpm for 5 min. Then the supernatants were
cleared of heavier debris by spins at 10,000 × g for 30 min and 30,000 × g for 1 h. Exosomes were then spun down at 110,000 × g for 4–20 h. Exosome
pellets were washed in PBS at 110,000 × g for 1.5 h – overnight. Some exosomes were further purified using a density gradient Optiprep (Sigma-Aldrich).
Optiprep was diluted with PBS to produce the following layers: 5, 10, 15, 20, 30, 40, and 50 % w/v (densities of 1.031, 1.050, 1.084, 1.110,
1.163, 1.215, and 1.268 g/mL). The expected size of exosomes is between 25 and 135 nm and >70 % of the EVs isolated fall into this
range (red area). c Representative diagram showing that we find more exosomes in RA (yellow and blue areas) compared to OA (blue area only) in
fibroblast supernatants. d and e Whole and lysed (0.5 % Triton X-100) exosome fractions were then measured for Id1. We found that >80 % of the
detected Id1 is contained within RA fibroblast cell supernatant exosomes. We similarly found that OA and RA SF have exosomes containing Id1
(n = number of sample wells measured for exosomes isolated from SF specimens from two separate patients for OA; and three separate patients for RA).
All data was pooled in the respective OA and RA SF groups. Id1 inhibitor of DNA binding 1, OA osteoarthritis, RA rheumatoid arthritis, SF synovial fluid
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Fig. 5 Id1 signals through the *pJnk pathway in HMVECs and EPCs. HMVECs and EPCs were cultured in 6-well plates and stimulated at different
time intervals with human recombinant Id1. The cell lysate was collected and western blot analysis was performed. The results are shown as fold
increase from the nonstimulated (NS), which was arbitrarily set at 1. The upper band represents phosphorylated signaling molecule (*p) and the
lower band represents total signaling molecule. Using these bands, the amount of phosphorylated signaling molecule was quantified for each
respective blot and results pooled. Upregulation (↑) of *pJnk and *pP38 was statistically significant in EPCs and upregulation of *pJnk was
statistically significant in HMVECs. Upregulation of *pJnk plateaued at 5 min in EPCs and later in HMVECs at 30 min. Other signaling molecules
were tested but results were not significant (data not shown, n = number of experimental replicates; the delta symbol with slash represents no
change. EPC endothelial progenitor cell, HMVEC human dermal microvascular endothelial cell, Id1 inhibitor of DNA binding 1, NS nonstimulated
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Fig. 6 Jnk siRNA lowers HMVEC-mediated angiogenesis in the Matrigel plug assay. HMVECs were transfected with either control or Jnk siRNA
designed to inhibit the Jnk signaling pathway. These cells were combined with 10 nM Id1 in Matrigel, which was injected subcutaneously into mice.
Five days later, the Matrigel plug was removed, weighed, and homogenized. The hemoglobin assay was run to determine amount of hemoglobin in
the plugs as a marker of angiogenesis. Jnk siRNA significantly inhibited angiogenesis in this assay. HMVEC human dermal microvascular endothelial cell,
Id1 inhibitor of DNA binding 1, siRNA silencing RNA
Edhayan et al. Arthritis Research & Therapy  (2016) 18:87 Page 9 of 12
the EV fraction over a discontinuous Optiprep density
gradient with seven fractions from 1.268 g/mL to
1.031 g/mL and collected the fractions containing exo-
somes. Id1 was barely detected on the surface of
exosomes or on other EVs of similar density. However,
addition of Triton X-100 (which lyses exosomes) re-
vealed that >80 % of the detected Id1 is contained within
exosomes, indicating that fibroblasts likely utilize exoso-
mal mechanisms for Id1 export from the nucleus to the
cytoplasm and out of the cell.
Id1 is also expressed at high levels in pro-B cells, but is
downregulated in pre-B cells and mature B cells [36, 37].
Constitutive expression of Id1 in transgenic mice shows
that these animals display severe defects in the develop-
ment of B cells, demonstrating that cells in early develop-
ment express Id1 and subsequently downregulate it as
they acquire a mature phenotype [36]. It is possible that
mature cells in the RA joint may take up fibroblast-
derived Id1 (released within exosomes) to regulate cell
proliferation in the inflammatory milieu of the RA syno-
vium. Cellular crosstalk mediated by Id1 could thus trans-
fer information from one cell to another despite inability
of many inflammatory cells in the RA synovium to make
Id1. Similarly, it was recently reported by Bourdonnay et
al. that alveolar macrophages secrete the STAT-induced
STAT signaling inhibitors SOCS1 and SOCS3 in exosomes
and microparticles, respectively, for uptake by alveolar
epithelial cells and subsequent inhibition of STAT activa-
tion in vitro and in vivo [38].
Kim et al. have generated transgenic mice in which
Id1 is expressed specifically in T cells with the total
number of thymocytes in these mice observed to be less
than 4 % of that in Wt mice [39], again demonstrating
the repressive nature of Id1 when overexpressed. Most
cells were CD4-/CD8- double-negative cells bearing cell
surface markers of multipotent progenitor cells, with
apoptotic cells constituting about 50 % of the total
thymocytes. Also of note, Tanaka et al. reported that the ex-
pression of Id1 in cardiac myocytes leads to the induction
of apoptosis through a redox-dependent mechanism [40].
As previously noted, Id1 is upregulated in RA SF, and
we show herein that Id1 initiates cell signaling events via
an as yet unknown receptor. We did find that Id1 stimu-
lates EPC signaling through *pP38 and *pJnk at almost
all times measured, but not through Erk½ or PI3k. Peak
upregulation of *pP38 and *pJnk was found at a stimula-
tion time of approximately 5 min and persisted for at
least 45 min. This is in contrast to HMVECs that dis-
played a more delayed and subtle response to Id1, show-
ing significance in *pJnk expression after 15 min, then
plateauing at 30 min. The kinetics of HMVEC and EPC
signaling in response to Id1 with respect to *pJnk reveals
differences in these cells, with the mature ECs showing a
weaker response to Id1 than EPCs. Nonetheless, this
experiment does show that it is possible for *pJnk to be
a common signaling molecule in both EPCs and
HMVECs when these cells are stimulated with Id1. This
finding also identifies EPCs and ECs as cells able to
bind Id1, further characterizing Id1 as both a vasculo-
genic and angiogenic mediator in the RA joint [12].
Locating where cell signaling events intersect in ma-
ture or progenitor ECs could be used to identify targets
for Id1 inhibition and unwanted angiogeneic activity.
We have performed similar signaling experiments on RA
synovial fibroblasts as shown here for ECs and found that
they signal through *pP38, *pJnk, *pJak2 and *pNF-κB in
response to Id1 (data not shown), thus providing further
evidence that Id1 may induce similar signaling events/
pathways in various cell types. Of special note is the data
(presented in Fig. 6) showing that inhibition of Jnk in
HMVECs with siRNA significantly reduces the amount of
Id1-induced Hb in the mouse Matrigel plug angiogenesis
assay. Hb is a direct measure of angiogenesis, and we
show that Jnk inhibition significantly reduced Id1-driven
blood vessel formation in vivo. This finding demonstrates
the feasibility of using signaling inhibition to disrupt
essential pro-inflammatory functions (e.g., angiogenesis)
initiated by Id1. Finally, it should be noted that the signal-
ing and angiogenesis activity was shown using recombin-
ant Id1, and not Id1 isolated from exosomes taken from
RA SF or from fibroblast cell culture supernatants. In fu-
ture studies, it would be interesting to examine the activity
of exosome-derived Id1 for potential epigenetic alterations
of the molecule, and if found, how they might affect Id1
activity.
The current standard of care for RA patients includes
inflammatory cytokine inhibition. Hence, blockade of
tumor necrosis factor-α (TNF-α) has resulted in im-
proved pain control and decreased structural deformity
in this disease. However, it is well documented that
nearly one third of RA patients do not benefit from anti-
TNF-α therapy. We posit that Id1 plays a central role in
RA pathogenesis, independent of TNF-α, by expanding
the vascular network. Overall, our data is suggestive that
fibroblast-derived Id1 may contribute to vasculogenesis
as well as angiogenesis by independent mechanisms, and
that soluble Id1 can serve as either a biomarker or thera-
peutic target for angiogenesis in RA tissues.
Conclusions
We show that Id1 is a pleiotropic nuclear protein exhibit-
ing multiple functions including roles in angiogenesis,
vasculogenesis, cell growth, and cellular self-renewal. We
show that Id1 is released from fibroblasts and initiates cell
activation, angiogenic and pro-inflammatory properties.
We identify Id1 as a fibroblast-derived inflammatory pro-
tein capable of functioning as a signaling agonist, regula-
tory molecule, and angiogenic mediator in RA tissues.
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